MedTrace Logo

MEV for Retroclavicular Approach to Infraclavicular Block

NCT03555786 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2020-04-30

No results posted yet for this study

Summary

In this study, the primary objective was to estimate the minimum effective volume of bupivacaine 0.5% resulting in successful block in 90% of patients (MEV90) for ultrasound-guided retroclavicular approach to infraclavicular brachial plexus block.

Conditions

  • Bupivacaine

Interventions

OTHER

minimum effective volume

The determination of MEV90 and its 95% confidence interval (CI) will be based on a "biased coin up-and-down sequential design

Sponsors & Collaborators

  • Antalya Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Ali Sait Kavakli, MD · Antalya Training and Research Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2018-08-01
Completion
2018-09-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03555786 on ClinicalTrials.gov